Back to top

NewAmsterdam Pharma price target raised to $51 from $47 at RBC Capital

RBC Capital raised the firm’s price target on NewAmsterdam Pharma (NAMS) to $51 from $47 and keeps an Outperform rating on the shares. The firm’s p...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

NewAmsterdam Pharma Company N.V. (NAMS)